Clinical Edge Journal Scan

Atopic dermatitis decreases lung function in infants


 

Key clinical point: Infants with atopic dermatitis (AD) experience significant bronchial obstruction regardless of disease severity, food sensitivity, and a history of recurrent wheezing.

Major finding: Tidal breath analysis revealed that the AD vs control group had significantly lower time to peak tidal expiratory flow (TPTEF; P = .001), exhaled volume to peak tidal expiratory flow (VPTEF; P = .001), TPTEF/expiratory time ( P < .001), VPTEF/total expiratory volume ( P < .001), expiratory flow when 25% of tidal volume remains in the lungs ( P < .001), and respiratory rate ( P = .007 ), with no differences observed within the AD group when these parameters were compared based on disease severity, food sensitivity, and a history of recurrent wheezing (all P > .05).

Study details: This prospective cross-sectional study included 150 infants aged 0-3 years with AD and 80 control infants of similar age without chronic disease, acute or chronic infection, history of prematurity, developmental delay, neurometabolic disease, or atopy.

Disclosures: This study did not receive any funding. The authors declared no conflicts of interest.

Source: Koksal ZG and Uysal P. Beyond the skin: Reduced lung function associated with atopic dermatitis in infants. J Allergy Clin Immunol Pract. 2023 (Jul 3). Doi: 10.1016/j.jaip.2023.06.055

Recommended Reading

JAK inhibitors efficacious for atopic dermatitis in Asian patients, study finds
MDedge Dermatology
Camp Discovery: A place for children to be comfortable in their own skin
MDedge Dermatology
Ocular complications of dermatologic treatments: Advice from a pediatric ophthalmologist
MDedge Dermatology
When treating AD in children, experts consider adherence, other aspects of treatment
MDedge Dermatology
Phase 3 trial supports long-term efficacy and safety of abrocitinib in moderate-to-severe atopic dermatitis
MDedge Dermatology
Lebrikizumab shows favorable benefit-risk profile in adolescents with moderate-to-severe atopic dermatitis
MDedge Dermatology
Atopic dermatitis not associated with malignancy overall but increases the risk for lymphoma
MDedge Dermatology
Dupilumab rapidly reduces Staphylococcus aureus abundance in moderate-to-severe atopic dermatitis
MDedge Dermatology
Upadacitinib offers long-term benefits against treatment-resistant moderate-to-severe atopic dermatitis
MDedge Dermatology
Baricitinib improves outcomes in moderate-to-severe atopic dermatitis
MDedge Dermatology